Charles Farthing

5.3k total citations · 1 hit paper
46 papers, 4.0k citations indexed

About

Charles Farthing is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Charles Farthing has authored 46 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 18 papers in Virology and 15 papers in Epidemiology. Recurrent topics in Charles Farthing's work include HIV Research and Treatment (18 papers), HIV/AIDS drug development and treatment (17 papers) and HIV/AIDS Research and Interventions (13 papers). Charles Farthing is often cited by papers focused on HIV Research and Treatment (18 papers), HIV/AIDS drug development and treatment (17 papers) and HIV/AIDS Research and Interventions (13 papers). Charles Farthing collaborates with scholars based in United States, United Kingdom and India. Charles Farthing's co-authors include David D. Ho, Richard A. Koup, Yaming Cao, Jeffrey T. Safrit, Gavin X. McLeod, William Borkowsky, Charla Andrews, Calvin Cohen, Martin Markowitz and R.C.D. Staughton and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Clinical Infectious Diseases.

In The Last Decade

Charles Farthing

46 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

1994 2.0k citations Charles Farthing et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Farthing United States	22	3.0k	1.9k	1.7k	1.1k	373	46	4.0k
Birgitta Åsjö Sweden	32	3.1k 1.0×	2.1k 1.1×	1.4k 0.9×	1.0k 1.0×	522 1.4×	75	4.3k
Mary Zupancic United States	16	2.8k 0.9×	1.6k 0.8×	1.4k 0.9×	822 0.8×	450 1.2×	23	3.5k
Éva Mária Fenyõ Sweden	38	3.5k 1.2×	2.2k 1.1×	1.9k 1.2×	923 0.9×	741 2.0×	116	4.6k
Oren J. Cohen United States	27	2.5k 0.9×	1.4k 0.7×	1.7k 1.0×	897 0.8×	438 1.2×	43	3.6k
Rémi Cheynier France	35	2.9k 1.0×	1.6k 0.8×	2.2k 1.3×	1.1k 1.0×	610 1.6×	85	4.5k
Cecil H. Fox United States	26	3.7k 1.2×	2.2k 1.1×	1.9k 1.2×	1.2k 1.2×	502 1.3×	60	5.1k
James F. Demarest United States	25	3.9k 1.3×	2.0k 1.0×	2.7k 1.6×	1.2k 1.2×	418 1.1×	46	5.1k
A S Fauci United States	34	3.4k 1.1×	2.1k 1.1×	2.3k 1.4×	1.2k 1.1×	613 1.6×	52	5.1k
Frank de Wolf Netherlands	33	3.1k 1.0×	2.5k 1.3×	1.1k 0.7×	1.1k 1.0×	421 1.1×	67	4.4k
Frank Miedema Netherlands	29	2.4k 0.8×	1.4k 0.7×	1.6k 1.0×	899 0.8×	289 0.8×	68	3.4k

Countries citing papers authored by Charles Farthing

Since Specialization

Citations

This map shows the geographic impact of Charles Farthing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Farthing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Farthing more than expected).

Fields of papers citing papers by Charles Farthing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Farthing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Farthing. The network helps show where Charles Farthing may publish in the future.

Co-authorship network of co-authors of Charles Farthing

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Farthing. A scholar is included among the top collaborators of Charles Farthing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Farthing. Charles Farthing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zheng, Y., et al.. (2012). Study on clinical epidemiology of Male HIV/AIDS patients in a tertiary Chinese hospital, Shanghai, China. Public Health. 127(1). 76–78. 3 indexed citations

Grant, Philip, Jonathan Taylor, William R. Short, et al.. (2009). Maintaining Reduced Viral Fitness and CD4 Response in HIV‐Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. Clinical Infectious Diseases. 48(5). 680–682. 3 indexed citations

Clotet, Bonaventura, Jean‐Michel Molina, David A. Cooper, et al.. (2007). Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. The Lancet. 369(9568). 1169–1178. 367 indexed citations

Gathe, Joseph, David A. Cooper, Charles Farthing, et al.. (2006). Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial. Clinical Infectious Diseases. 43(10). 1337–1346. 67 indexed citations

DeJesus, Edwin, Daniel Berger, Martin Markowitz, et al.. (2006). Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(1). 1–5. 223 indexed citations

Lori, Franco, Richard B. Pollard, Lucia Whitman, et al.. (2005). Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency. AIDS Research and Human Retroviruses. 21(4). 263–272. 9 indexed citations

Khanlou, Homayoun, et al.. (2005). Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Review of Anti-infective Therapy. 3(1). 9–21. 17 indexed citations

DeJesus, E, Dennis McCarty, Charles Farthing, et al.. (2004). Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial. Clinical Infectious Diseases. 39(3). 411–418. 50 indexed citations

Fischl, Margaret A., Charles Farthing, Melanie Thompson, et al.. (2003). Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(11). 1432–1440. 1 indexed citations

10.

Cohen, Calvin, Susan C. Hunt, Michael Sension, et al.. (2002). A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 16(4). 579–588. 126 indexed citations

11.

Jacobson, Jeffrey M., Richard Hafner, Jack S. Remington, et al.. (2001). Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS. 15(5). 583–589. 30 indexed citations

12.

Sension, Michael, et al.. (2001). Challenges of Antiretroviral Treatment in Transient and Drug-Using Populations: The SUN Study. AIDS Patient Care and STDs. 15(3). 129–136. 4 indexed citations

13.

Khanlou, Homayoun, et al.. (2000). Development of Kaposi Sarcoma Despite Sustained Suppression of HIV Plasma Viremia. JAIDS Journal of Acquired Immune Deficiency Syndromes. 23(4). 361–361. 4 indexed citations

14.

Nichols, W. Stephen, et al.. (1999). Increased CD4⁺ T‐Lymphocyte Senescence Fraction in Advanced Human Immunodeficiency Virus Type 1 Infection. Scandinavian Journal of Immunology. 49(3). 302–306. 24 indexed citations

15.

Kessler, Harold A., S S Hurwitz, Charles Farthing, et al.. (1996). Pilot Study of Topical Trifluridine for the Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients with AIDS (ACTG 172). Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 12(2). 147–152. 26 indexed citations

16.

Zhu, Tuofu, et al.. (1993). Idiopathic CD4+ T-Lymphocytopenia -- Immunodeficiency without Evidence of HIV Infection. New England Journal of Medicine. 328(6). 380–385. 101 indexed citations

17.

Cooper, David A., P Pehrson, Court Pedersen, et al.. (1993). The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex. AIDS. 7(2). 197–208. 63 indexed citations

18.

Youle, M, David Hawkins, Charles Farthing, et al.. (1989). The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.. PubMed. 70(262). 161–74. 19 indexed citations

19.

Youle, M, Charles Farthing, Maureen Connolly, et al.. (1989). Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.. BMJ. 298(6671). 432.1–432. 104 indexed citations

20.

Farthing, Charles. (1985). Points : Pneumonia in the acquired immune deficiency syndrome. BMJ. 290(6484). 1829.6–1829. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact